Cargando…
Improvement of Cardiac Vegetations in Antiphospholipid Syndrome with Enoxaparin and Corticosteroids after Rivaroxaban Failure
Cardiac disease is a well-known complication of antiphospholipid syndrome (APS), with many patients presenting with valvular thickening or vegetations, referred to as Libman–Sacks endocarditis (LSE). Because cases of APS with cardiac involvement are relatively rare, paucity of large clinical trials...
Autores principales: | Granowicz, Eric, Chung, Kiyon |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6151239/ https://www.ncbi.nlm.nih.gov/pubmed/30271642 http://dx.doi.org/10.1155/2018/8097539 |
Ejemplares similares
-
Comparison of Enoxaparin and Rivaroxaban in the Prophylaxis of Deep Venous Thrombosis in Arthroplasty
por: Çiçek, Necati, et al.
Publicado: (2021) -
Adrenal failure and antiphospholipid syndrome
por: Mlekuš Kozamernik, Katarina, et al.
Publicado: (2020) -
A single-arm feasibility cohort study of rivaroxaban in antiphospholipid syndrome
por: Legault, Kimberly, et al.
Publicado: (2020) -
Rivaroxaban in antiphospholipid syndrome (RAPS) protocol: a prospective, randomized controlled phase II/III clinical trial of rivaroxaban versus warfarin in patients with thrombotic antiphospholipid syndrome, with or without SLE
por: Cohen, H, et al.
Publicado: (2015) -
Rivaroxaban Versus Enoxaparin for Thromboprophylaxis After major
Gynecological Cancer Surgery: The VALERIA Trial: Venous thromboembolism
prophylAxis after
gynecoLogical pElvic cancer
surgery with RIvaroxaban versus
enoxAparin (VALERIA trial)
por: Longo de Oliveira, André Luiz Malavasi, et al.
Publicado: (2022)